Daiichi Sankyo to divest certain cardiovascular and other legacy products to Cosette Pharmaceuticals in the US, shifting focus to oncology portfolio

Daiichi Sankyo Company Limited and Daiichi Sankyo Inc (hereafter, Daiichi Sankyo) have entered into an agreement with Cosette Pharmaceuticals Inc whereby Daiichi Sankyo divested and Cosette acquired rights for manufacturing, commercialization, and certain other rights for the following products in the US: AZOR (amlodipine/olmesartan medoxomil); BENICAR (olmesartan medoxomil); BENICAR HCT (olmesartan medoxomil/hydrochlorothiazide); EFFIENT (prasugrel); EVOXAC (cevimeline HCL); TRIBENZOR (olmesartan medoxomil/amlodipine/hydrochlorothiazide); WELCHOL (colesevelam HCL) tablets; WELCHOL (colesevelam HCL) Oral Suspension. No other products are impacted by this agreement and no roles will be eliminated at Daiichi Sankyo related to this agreement. The agreement outlines a 30-month transition period during which Daiichi Sankyo and Cosette Pharmaceuticals will transfer responsibilities for the manufacture, supply and commercialization of these products, including quality assurance, pharmacovigilance and regulatory matters. Original source: Daiichi Sankyo Co Ltd, website: http://www.daiichisankyo.com/, Copyright Daiichi Sankyo Company Limited 2022.
mergers and acquisitions; patents and technical know-how; amlodipine; AZOR; BENICAR HCT; cevimeline; cevimeline hydrochloride; colesevelam hydrochloride; colesevelam hydrochloride; hydrochlorothiazide; olmesartan medoxomil; olmesartan medoxomil; prasugrel; prasugrel; TRIBENZOR; Cosette Pharmaceuticals; Daiichi [...]